ArticleJournal of thoracic disease2026
3D-printing on human acellular dermis for chest wall reconstructions-an
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Massive bone or tissue defects caused by trauma, tumors or infections are a frequently occurring clinical problem. Novel biomaterials combined with new technologies offer new treatment options especially regarding reconstruction of bone and tissue. Aim of this study was to establish the stable and biocompatible combination of decellularized human dermis with a stable polymer via three-dimensional (3D) printing. Methods: Polylactide (PLA) models were 3D-printed onto human acellular dermis (hAD) membranes using FreeCAD (computer-aided design) software for modeling and Ultimaker 2+ for printing. Cytotoxicity was assessed using L929 fibroblast cells in an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid (MTT) assay analogue to DIN EN ISO 10993-5 guidelines. Laser microtome sectioning was performed to enable histological analysis involving hematoxylin-eosin (HE) staining for tissue morphology assessment. The chorioallantoic membrane (CAM) assay was conducted on fertilized chicken eggs to evaluate cytotoxic effects and vascular ingrowth, by microscopic imaging. Results: PLA was successfully 3D-printed onto hAD, forming a stable bond. After 72 hours of incubation in PBS, the printed structure remained securely attached. Histological analysis confirmed the integrity of the collagen structure after printing with high temperatures, with only slight compression in the top layer of the hAD. Cytotoxicity testing according to ISO 10993-5 showed no significant reduction in cell viability (83%), thereby demonstrating biocompatibility. The CAM assay demonstrated vascular integration, with vessels forming around and connecting to the hybrid material. Conclusions: The successful 3D printing of PLA onto hAD resulted in a stable hybrid material with preserved structural integrity and good fluid resistance. Histological and cytotoxicity analyses confirmed biocompatibility, while the CAM assay demonstrated vascular integration. These findings suggest that the hAD-PLA composite holds potential for biomedical applications, particularly in tissue engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.